Corus Pharma Report issue

For profit Phase 3
Founded: Seattle WA United States (2001)
Status: Acquired by Gilead Sciences (2006)

Organization Overview

First Clinical Trial
2005
NCT00112359
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2005

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Corus Pharma, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

azlocillin (azlin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cystic Fibrosis (Phase 3)

Fibrosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1